ReviewFrontiers in immunology2026
Immune regulation and therapeutic targets in sepsis: insights from single-cell transcriptomics.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a life-threatening systemic inflammatory syndrome often associated with immune dysregulation, multi-organ dysfunction, and high mortality. In recent years, single-cell transcriptomics has generated a wealth of data on immune cell heterogeneity, lineage reprogramming, and functional states in sepsis. However, a systematic integration and summary of immune cell subsets and regulatory mechanisms are still lacking, limiting a comprehensive understanding of dynamic immune responses and potential therapeutic targets across disease progression. This review synthesizes advances from single-cell and multi-omics studies in sepsis, highlighting myeloid-biased hematopoietic stem/progenitor cell differentiation and emergency granulopoiesis, immunosuppressive features of neutrophils and MDSCs, T/NK cell exhaustion and metabolic adaptation, B cell and plasma cell reprogramming, and glial cell polarization affecting the blood-brain barrier. Key molecular mechanisms, including TLR4 acetylation, STAT3-CEBPB axis, Fu-Hp/Mincle signaling, Treg metabolism, and the kynurenine pathway, are discussed, alongside potential biomarkers and therapeutic targets such as inflammatory CD16
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.